1. Market Research
  2. > Pharmaceutical
  3. > Drug Discovery and Development Market Trends
  4. > Latest Guidebook for Conducting Pharma Clinical Trials in China: From Regulations to Practice

Latest Guidebook for Conducting Pharma Clinical Trials in China: From Regulations to Practice

  • August 2014
  • -
  • Access China Management Consulting Ltd.
  • -
  • 191 pages

China is one of the fastest growing global economies with a fifth population in the world, and is one of the largest healthcare markets around the world. Along with sustained economic and population growth as well as an ageing opulation, Chinese healthcare market has maintained annually average growth rate bove 16 % since 1990s. By 2013, total value of drugs on Chinese healthcare market has reached RMB 1114 billion. On the Chinese healthcare market, imported drugs made by overseas and multinational pharmaceutical manufacturers account for about one fourth. It is estimated that total value of drugs on Chinese healthcare market will be likely to be more than RMB 1450 billion by 2015, and will surpass Japan to become the second largest drug market following the United States. The Chinese healthcare market will attract more and more overseas pharmaceutical manufacturers and producers to penetrate such market. Many overseas and multinational pharmaceutical manufacturers are ardently conducting clinical trials for their drugs in China to seize a larger part of such drug market. However, the Chinese approach to GCP compliance is unique, from the application and approval process, the requirements for ethics committees, sponsors and investigators to the application dossiers. To enter such a lucrative drug market, overseas and multinational pharmaceutical manufacturers and producers must have a comprehensive and thorough knowledge of the latest Chinese regulations on clinical trials. Otherwise, the restrictive legal requirements and approval delays eat up your development time and budget.

This Latest Guidebook for Conducting Pharma Clinical Trials in China: From Regulations to Practice not only provided a comprehensive and thorough knowledge of the latest Chinese regulations on clinical trials for imported drug registration but also introdued the practical operation how to comply with the Chinese GCP to guide you use the Chinese trial venues to keep drug development lean and agile in the “post-patent-cliff” world step by step.

The organizations of this guidebook are arranged as follows. Chapter 2 provides an overview of the Chinese applicable laws and regulations for drug clinical trials. Chapter 3 introduced an overview of Chinese regulatory authorities for drug clinical trials to give the direction of gateway for clinical trials of imported drugs. Chapter 4 elaborated the definitions of some basic terms used in application and approval process of clinical trials for drug registration and the Chinese unique classification of drug registration, from the chemical drugs, biological products, natural medicines to traditional Chinese medicines (TCMs). Chapter 5 introduced the general regulations on application and approval for clinical trials of imported drug registration. Chapter 6 introduced the every party’s responsibilities in clinical trials for imported drug registration.

Chapter 7 delineated an entrie process of application and approval procedures for clinical trials of imported drug registration. Chapter 8 provided the full text in English of “Drug Registration Application Form for Imported Drug” to guide you fill it step by step. Chapter 9 gave the practical guidance for clinical trials of imported chemical drug registration, from the general and special regulations on clinical trials for imported chemical drug registration, the requirements for data and materials of application for approval of clinical trials for imported chemical drugs to the data and materials submission of application for approval of clinical trials for imported chemical drugs. Chapter 10 provided the practical guidance for clinical trials of imported biological product registration, also from the general and special regulations on clinical trials for imported biological product registration, the requirements for data and materials of application for approval of clinical trials for imported biological products to the data and materials submission of application for approval of clinical trials for imported biological products. Chapter 11 introduced the practical guidance for clinical trials of imported natural medicine and traditional Chinese medicine registration, again from the general and special regulations on clinical trials for imported natural medicine and traditional Chinese medicine registration, the the requirements for data and materials of application for approval of clinical trials for imported natural medicines and traditional Chinese medicines to the data and materials submission of application for approval of clinical trials for imported natural medicines and traditional Chinese medicines. Chapter 12 Appendices provided the full text in English of “Drug Administration Law of the People’s Republic of China”, “Regulations for Implementation of the Drug Administration Law of the People’s Republic of China” and “The Chinese Good Clinical Practice of Pharmaceutical Products”.

The audiences of this guidebook are overseas pharmaceutical companies wishing to enter into the Chinese drug market, and multinational pharmaceutical companies have penetrated into the Chinese drug market, and their senior executive officers engaging in regulatory affairs expecting to understand how to conduct smoothly clinical trials for their pharmaceutical products in China, and how to comply with the Chinese GCP. After having skimmed through this guidebook, audiences can clearly acquire not only a comprehensive and thorough knowledge of Chinese regulations on clinical trials for imported drug registration but also the practical operation how to comply with the Chinese GCP. Access China Management Consulting Ltd hopes this guidebook, based on full and accurate regulations, can guide overseas and multinational pharmaceutical manufacturers and producers to achieve a successful entry into the Chinese drug clinical trial market, and smoothly operate clinical trial for their products in China.

Report Highlights
An overview of the Chinese applicable laws and regulations for drug clinical trials.
An overview of organizational structure of Chinese regulatory authorities for drug clinical trials to give the direction of gateway for clinical trials of imported drugs.
The Chinese definitions of some basic terms used in application and approval process of drug clinical trials for drug registration, and the Chinese unique classification of drug registration, from the chemical drugs, biological products, natural medicines to traditional Chinese medicines (TCMs).
Chinese unique every party’s responsibilities in clinical trials for imported drug registration.
An entrie process of application and approval procedures for clinical trials of imported drug registration.
The full text in English of “Drug Registration Application Form for Imported Drug”.
The practical guidance for clinical trials of imported chemical drug registration, from the general and special regulations on clinical trials for imported chemical drug registration, the requirements for data and materials of application for approval of clinical trials for imported chemical drugs to the data and materials submission of application for approval of clinical trials for imported chemical drugs to smoothly navigate complex regulatory requirements step by step.
The practical guidance for clinical trials of imported biological product registration, also from the general and special regulations on clinical trials for imported biological product registration, the requirements for data and materials of application for approval of clinical trials for imported biological products to the data and materials submission of application for approval of clinical trials for imported biological products to smoothly navigate complex regulatory requirements step by step.
The practical guidance for clinical trials of imported natural medicine and traditional Chinese medicine registration, again from the general and special regulations on clinical trials for imported natural medicine and traditional Chinese medicine registration, the requirements for data and materials of application for approval of clinical trials for imported natural medicines and traditional Chinese medicines to the data and materials submission of application for approval of clinical trials for imported natural medicines and traditional Chinese medicines to smoothly navigate complex regulatory requirements step by step..
A set of full text in English of Chinese laws and regulations for pharmaceutical product clinical trials.

Table Of Contents

Latest Guidebook for Conducting Pharma Clinical Trials in China: From Regulations to Practice
Table of Contents.1

Chapter 1 Executive Summary.4

Chapter 2 Chinese Applicable Laws and Regulations for Drug Clinical Trials.5

Chapter 3 An Overview of Chinese Authorities for Drug Clinical Trials.7
3.1. CFDA's Main Responsibilities.7
3.2. CFDA's Organizational Structure.9
Figure 3.2.1. CFDA's Organizational Structure.10
Table 3.2.1. CFDA's affiliated organizations.11
3.3. Roadmap of Application and Approval for Clinical Trials of Imported Drug Registration.13
Figure 3.3.1. Roadmap of Application and Approval for Clinical Trias of Imported Drug Registration.15

Chapter 4 Knowledge Preparation before conducting Imported Drug Clinical Trials.16
4.1. Definitions.16
4.2. Classification of Drugs.18
4.2.1. Classification of Chemical Drugs.19
4.2.2. Classification of Biological Products.20
4.2.2.1. Classification of Therapeutic Biological Products.20
4.2.2.2. Classification of Prophylactic Biological Products.21
4.2.3. Classification of Natural Medicines and Traditional Chinese Medicines (TCMs).22

Chapter 5 General Regulations on Application and Approval for Clinical Trials of Imported Drug Registration.24
5.1. General Regulations on Application and Approval for Clinical Trials of Imported Drug Registration.24
5.2. Special Regulations for Imported Drug Clinical Trials.27

Chapter 6 Every Party's Responsibilities in Clinical Trials for Imported Drug Registration.32
6.1. The Sponsor's Responsibilities.32
6.2. The Monitor's Responsibilities.35
6.3. The Ethics Committee's Responsibilities.37
6.4. The Investigator's Responsibilities.38.

Chapter 7 Application and Approval Procedures for Clinical Trials of Imported Drug Registration.40
Figure 7.1. An Entrie Process of Application and Approval Procedures for Imported Drug Registration.41
Figure 7.2. Application and Approval Procedure for Clinical Trials.43

Chapter 8 Application Form for Imported Drug Registration.44
8.1. Drug Registration Application Form for Imported Drug.44
Table 8.1. Drug Registration Application Form for Imported Drug.45
8.2. Explanatory Notes for filling Drug Registration Application Form for Imported Drug.51

Chapter 9 Practical Guidance for Clinical Trials of Imported Chemical Drug Registration.53
9.1. General Regulations on Clinical Trials for Chemical Drug Registration.53
9.2. Special Regulations for Imported Chemical Drug Clinical Trials.55
9.3. Data and Materils of Application for Approval of Clinical Trials for Imported Chemical Drug Registration. 57
9.3.1. Data Items of Application for Approval of Imported Chemical Drug Clinical Trials.57
9.3.2. Requirements for Data and Materials of Application for Approval
of Imported Chemical Drug Clinical Trials.64
9.3.3. Explanatory Notes for Data and Materials of Application for Approval of Imported Chemical Drug Clinical Trials.66
9.3.4. Data and Materials submission of Application for Approval of Imported Chemical Drug Clinical Trials.70

Chapter 10 Practical Guidance for Clinical Trials of Imported Biological Product Registration.72
10.1. Practical Guidance for Clinical Trials of Imported Therapeutic Biological Product Registration.72
10.1.1. General Regulations on Clinical Trials for Imported Therapeutic Biological Product Registration.72
10.1.2. Special Regulations for Imported Therapeutic Biological Product Clinical Trials.73
10.1.3. Data and Materils of Application for Approval of Clinical Trials for Imported Therapeutic Biological Product Registration.74
10.1.4. Requirements for Data and Materials of Application for Approval of Imported Therapeutic Biological Product Clinical Trials.80
10.1.5. Explanatory Notes for Data and Materials of Application for Approval of Imported Therapeutic Biological Product Clinical Trials.84
10.1.6. Data and Materials submission of Application for Approval of Imported Therapeutic Biological Product Clinical Trials.91
10.2. Practical Guidance for Clinical Trials of Imported Preventive Biological Product Clinical Trials.93
10.2.1. General Regulations on Clinical Trials for Preventive Biological Product Registration.94
10.2.2. Special Regulations for Imported Preventive Biological Product Clinical Trials.95
10.2.3. Data and Materils of Application for Approval of Clinical Trials for Imported Preventive Biological Product Registration.95
10.2.4. Requirements for Data and Materials of Application for Approval of Imported Preventive Biological Product Clinical Trials.103
10.2.5. Explanatory Notes for Data and Materials of Application for Approval of Imported Preventive Biological Product Clinical Trials.104
10.2.6. Data and Materials submission of Application for Approval of Imported Preventive Biological Product Clinical Trials.105

Chapter 11 Practical Guidance for Clinical Trials of Imported Natural Medicine and Traditional Chinese Medicine Registration..108
11.1. General Regulations on Clinical Trials for Natural Medicine and Traditional Chinese Medicine Registration. 108
11.2. Special Regulations for Clinical Trials of Imported Natural Medicine and Traditional Chinese Medicine Registration.109
11.3. Data and Materils of Application for Approval of Clinical Trials for Imported Natural Medicine and Traditional Chinese Medicine Registration.109
11.4. Requirements for Data and Materials of Application for Approval of Clinical Trials for Imported Natural Medicines and Traditional Chinese Medicines.115
11.5. Explanatory Notes for Data and Materials of Application for Approval of Clinical Trials of Imported Natural Medicines and Traditional Chinese Medicines.117
11.6. Data and Materials Submission of Application for Approval of Clinical Trials of Imported Natural Medicines and Traditional Chinese Medicines.121

Chapter 12 Appendices.123
12.1. The Drug Administration Law of the People's Republic of China.123
12.2. The Regulations for Implementation of the Drug Administration Law of the People's Republic of China.148
12.3. The Good Clinical Practice of Pharmaceutical Products.172

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Clinical Trial Management System Market by End-user, Delivery Mode, Type, Component - Global Forecast to 2021

Clinical Trial Management System Market by End-user, Delivery Mode, Type, Component - Global Forecast to 2021

  • $ 5650
  • Industry report
  • August 2016
  • by MarketsandMarkets

The global clinical trial management system (CTMS) market is estimated to grow at a CAGR of 11.5% from 2016 to 2021, to reach USD 920.0 billion by 2021. The adoption of CTMS software is on the rise across ...

Contract Research Organizations Services Market by Type, Therapeutic Area, End User - Global Forecast to 2021

Contract Research Organizations Services Market by Type, Therapeutic Area, End User - Global Forecast to 2021

  • $ 5650
  • Industry report
  • October 2016
  • by MarketsandMarkets

The global CRO services market is estimated to grow at a CAGR of 7.4% from 2016 to 2021, to reach USD 41.86 billion by 2021 from USD 29.29 billion in 2016. Growth in this market is primarily attributed ...

Clinical Trial Management System (CTMS) - Global Market Outlook (2016-2022)

Clinical Trial Management System (CTMS) - Global Market Outlook (2016-2022)

  • $ 4157
  • Industry report
  • November 2016
  • by Stratistics MRC

According to Stratistics MRC, the Global Clinical Trial Management System (CTMS) market is expected to grow from $493.58 million in 2015 to reach $1118.58 million by 2022 with a CAGR of 12.4%. Huge research ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.